<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271192</url>
  </required_header>
  <id_info>
    <org_study_id>GIHSYSU02</org_study_id>
    <nct_id>NCT01271192</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer</brief_title>
  <acronym>NARC</acronym>
  <official_title>A Randomized Multicenter Clinical Trial of Direct Surgical Resection Compared to Neoadjuvant Followed by Surgical Resection in Treating Patients With Operable Local Recurrent Carcinoma Of The Rectum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for&#xD;
      resectable local recurrent rectal cancer. However the efficacy and safety of adjuvant therapy&#xD;
      is still unknown.&#xD;
&#xD;
      PURPOSE: This randomized multicenter clinical trial is studying surgical resection followed&#xD;
      by chemo radiotherapy or neoadjuvant chemo radiotherapy followed by surgery and postoperative&#xD;
      chemotherapy, comparing them to see the efficacy and safety, then to investigate the effect&#xD;
      of adjuvant chemoradiotherapy for resectable local recurrent rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
      - Compare the 5-year survival rate in patients with resectable local recurrent rectal cancer&#xD;
      treated with either surgical resection or neoadjuvant.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the side effect of chemo radiotherapy according to the Common Toxicity&#xD;
           Criteria(CTC) version 2.0 in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the postoperative complications in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the recurrent rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the distant metastatic rate in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter clinical trial. Patients are stratified according&#xD;
      to participating center, gender, age. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4&#xD;
           weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6&#xD;
           weeks, from 8-12 weeks after operation.&#xD;
&#xD;
        -  Arm II: Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and&#xD;
           undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI&#xD;
           for 7 cycles from 2-4 weeks after operation.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, and&#xD;
      then every 6 months for at least 3 years.&#xD;
&#xD;
      The side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant&#xD;
      metastatic rate and 5-year survival rate will be investigated.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study within 5 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the 5-year survival rate in patients with resectable local recurrent rectal cancer treated with either surgical resection or neoadjuvant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the postoperative complications in patients treated with these regimens&#xD;
Compare the recurrent rate in these patients&#xD;
Compare the distant metastatic rate in these patients&#xD;
Compare preoperative quality of life (QOL) of patients.&#xD;
Compare the toxic effects of these regimens in these patients.&#xD;
Compare the convenience of care in patients treated with these regimens</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Surgical resection and adjuvant therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant followed by operation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical resection and adjuvant therapy</intervention_name>
    <description>Postoperative:&#xD;
Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks</description>
    <arm_group_label>Surgical resection and adjuvant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant followed by operation</intervention_name>
    <description>Preoperative:&#xD;
Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks&#xD;
Postoperative:&#xD;
Drug: fluorouracil Given IV continuously,Irinotecan Given IV</description>
    <arm_group_label>Neoadjuvant followed by operation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Adenocarcinoma of the rectum&#xD;
&#xD;
          2. Age:18-80 years old&#xD;
&#xD;
          3. Received curative resection when diagnosed as rectal cancer&#xD;
&#xD;
          4. Local recurrence happened &gt;6 months after operation,without distant metastasis&#xD;
&#xD;
          5. Local recurrent mass is resectable confirmed by surgeon and radiologist 6.15 days&#xD;
             prior recruit, meet the following criteria:&#xD;
&#xD;
               -  Hematopoietic&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2 times ULN&#xD;
&#xD;
               -  AST ≤ 2.5 times ULN&#xD;
&#xD;
               -  ALT ≤ 2.5 times ULN&#xD;
&#xD;
               -  No hepatic disease that would preclude study treatment or follow-up&#xD;
&#xD;
               -  No uncontrolled coagulopathy&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
               -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
               -  No renal disease that would preclude study treatment or follow-up&#xD;
&#xD;
        7.ECOG status: 0～1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other rectal cancers (i.e.sarcoma,lymphoma,carcinoid,squamous cell carcinoma,or&#xD;
             cloacogenic carcinoma)&#xD;
&#xD;
          2. Synchronous colon cancer&#xD;
&#xD;
          3. Hypersensitivity to fluorouracil&#xD;
&#xD;
          4. No More than 4 weeks since prior participation in any investigational drug study&#xD;
&#xD;
          5. Clear indication of involvement of the pelvic side walls by imaging With distant&#xD;
             metastasis&#xD;
&#xD;
          6. History of invasive rectal malignancy, regardless of disease-free interval Fertile&#xD;
             patients must use effective contraception&#xD;
&#xD;
          7. Uncontrolled hypertension&#xD;
&#xD;
          8. Cardiovascular disease that would preclude study treatment or follow-up&#xD;
&#xD;
          9. Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper&#xD;
             gastrointestinal tract bleeding&#xD;
&#xD;
         10. Pregnant or nursing, Fertile patients do not use effective contraception&#xD;
&#xD;
         11. Other malignancy within the past 5 years except effectively treated squamous cell or&#xD;
             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or&#xD;
             carcinoma in situ of the colon or rectum&#xD;
&#xD;
         12. No psychiatric or addictive disorders, or other conditions that, in the opinion of the&#xD;
             investigator, would preclude study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Lan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Lan, M.D.</last_name>
    <phone>008613710316769</phone>
    <email>lpzm@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastrointestinal Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pang Lan, M.D.</last_name>
      <phone>008613710316769</phone>
      <email>lpzm@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ping Lan</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>local recurrent rectal cancer</keyword>
  <keyword>surgical resection</keyword>
  <keyword>adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

